Specialties

Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Frankie Ann Holmes, MD, medical oncologist, Texas Oncology, discusses the implications of the results of the MA17R trial, which is a randomized phase III clinical trial that examined the benefits of extending aromatase inhibitors with letrozole as a treatment for postmenopausal patients with early breast cancer.
The Role of Early Tumor Shrinkage in Metastatic Colorectal Cancer
Early tumor shrinkage is linked to overall survival and could be a stronger surrogate marker than progression-free survival in metastatic colorectal cancer.
Matthew Yurgelun, MD, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer, as well as the next steps in identifying these mutations.

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the role of abiraterone acetate in the treatment of patients with prostate cancer, and the questions that remain about its use.

PSA Screening in Early-Stage Prostate Cancer Can Save Lives, Says Eggener
While the United States Preventative Services Task Force has taken a stand against routine prostate-specific antigen screening for prostate cancer, updated findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial could flip opinions.
Daratumumab Receives Breakthrough Designation for Use in Combo Treatments for Myeloma
Daratumumab (Darzalex) has been granted a breakthrough therapy designation by the FDA for use in the treatment of patients with multiple myeloma following at least 1 prior therapy. The CD38-targeted antibody is accepted for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone, according to Janssen, which is developing daratumumab with Genmab.
View More >

Features

Nivolumab Given Priority Review for Head and Neck Cancer
Nivolumab Given Priority Review for Head and Neck Cancer
The FDA has agreed to review nivolumab under an accelerated timeframe for its potential as a treatment for patients with previously treated metastatic or recurrent squamous cell carcinoma of the head and neck.
Understanding the Future of Immunotherapy in Melanoma
While there have been many recent advances in the field of melanoma regarding immunotherapy, there is still much more to come, says Antoni Ribas, MD, PhD.
Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL
With nearly a dozen new PI3K and BTK inhibitors currently in development, it is challenging to know which therapies are truly "next-generation" agents and which are "me too" products.
Shortcomings in SIRFLOX Design May Have Skewed PFS Findings
Shortcomings in the SIRFLOX study may have confounded the main findings, as the trial seemed plagued by a large number of confounding factors and a shifting trial design.
Novel Agent BION-1301 May Block Multiple Myeloma Cell Proliferation
BION-1301 may block multiple myeloma cell proliferation and reduce drug resistance and immunosuppression in the tumor microenvironment.
Publications